Medical Imaging Reagents Market Report 2026

The medical imaging reagents market size has grown strongly in recent years. It will grow from $16.27 billion in 2025 to $17.37 billion in 2026 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to advancement of diagnostic imaging modalities, rising prevalence of chronic diseases, increased use of contrast agents in radiology, growth of nuclear medicine procedures, expansion of hospital imaging infrastructure.

The medical imaging reagents market size is expected to see strong growth in the next few years. It will grow to $22.76 billion in 2030 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to growing demand for early disease detection, rising cancer and neurological disorder burden, increasing imaging procedure volumes, expansion of precision diagnostics, growth in clinical research activities. Major trends in the forecast period include growing demand for high-resolution diagnostic imaging, rising use of contrast reagents in chronic disease diagnosis, expansion of nuclear imaging in oncology applications, increasing focus on safety and biocompatibility of imaging reagents, higher adoption of multimodal imaging techniques.

The rising prevalence of chronic diseases is anticipated to drive the growth of the medical imaging reagents market in the coming years. Chronic diseases are conditions that persist for one year or more and require ongoing medical care, often worsening over time. These conditions rely heavily on medical imaging reagents for diagnosis and disease detection through the visualization of organs and affected tissues. For example, in February 2024, the Centers for Disease Control and Prevention (CDC), a U.S.-based federal public health agency, reported that approximately 129 million people in the United States are living with at least one major chronic disease, including heart disease, cancer, diabetes, obesity, and hypertension. Thus, the increasing burden of chronic diseases is fueling the expansion of the medical imaging reagents market.

Leading companies in the medical imaging reagents market are concentrating on the development of innovative offerings, such as cell painting kits, to boost their revenue growth. These kits contain pre-optimized and validated fluorescent probes along with a compatible diluent, enabling faster cell painting workflows with high batch-to-batch consistency and verified performance on high-content screening systems. For instance, in December 2023, Amazon Web Services (AWS), a U.S.-based company, advanced drug discovery through high-throughput Cell Painting, a sophisticated image-based assay used for high-content screening. This technique improves insights into cellular phenotypes and behaviors. By leveraging AWS’s scalable infrastructure, researchers can efficiently handle large datasets of cell images and conduct complex image analysis. The Cell Painting Batch solution on AWS, supported by tools such as CellProfiler, automates these workflows and overcomes challenges related to fluctuating workloads, collaboration barriers, and high computational requirements. As a result, this approach accelerates drug discovery while enhancing reproducibility and collaboration across research laboratories.

In December 2023, Mindray, a China-based multinational medical technology company engaged in the development and manufacture of medical equipment and accessories, acquired DiaSys Diagnostic Systems GmbH for an undisclosed sum. This acquisition enhances Mindray’s global supply chain capabilities and broadens its presence in the in-vitro diagnostics (IVD) segment. DiaSys Diagnostic Systems GmbH is a Germany-based manufacturing firm that focuses on the development and production of diagnostic system solutions, including automated clinical chemistry analyzers, semi-automated analyzers, and point-of-care instruments.

Major companies operating in the medical imaging reagents market are Lantheus Holdings Inc., Thermo Fisher Scientific Inc., Bayer AG, Bracco SpA, PerkinElmer Inc., SA Laboratoires André Guerbet, Guerbet Group, Merck KGaA, Curium Pharma, Nordion Inc., IBA Molecular, Eckert & Ziegler Radiopharma GmbH, Advanced Accelerator Applications, Jubilant Life Sciences Limited, Mallinckrodt Pharmaceuticals, CMC Contrast AB, Triad Isotopes Inc., Nihon Medi‑Physics Co Ltd, Eczacıbaşı‑Monrol Nuclear Products, Telix Pharmaceuticals, ITM Isotope Technologies Munich, Blue Earth Diagnostics Ltd., Navidea Biopharmaceuticals Inc.

North America was the largest region in the medical imaging reagents market in 2025. The regions covered in the medical imaging reagents market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the medical imaging reagents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs affect the medical imaging reagents market by increasing costs of imported raw materials, radioisotopes, and specialized chemical components. Diagnostic labs and pharmaceutical manufacturers in north america, europe, and asia-pacific are most impacted due to reliance on global suppliers. Higher tariffs can raise reagent prices and limit availability. However, they also encourage domestic manufacturing and local sourcing, supporting long-term supply chain resilience.

The medical imaging reagents market research report is one of a series of new reports that provides medical imaging reagents market statistics, including medical imaging reagents industry global market size, regional shares, competitors with a medical imaging reagents market share, detailed medical imaging reagents market segments, market trends and opportunities, and any further data you may need to thrive in the medical imaging reagents industry. This medical imaging reagents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Medical imaging reagents are substances used by healthcare professionals and researchers to improve the visibility of organs and anatomical structures, helping to detect new developments and support the diagnosis or treatment of diseases. These reagents enable clearer visualization of internal structures or organs, allowing clinicians to more accurately identify and assess medical conditions.

The primary categories of medical imaging reagents include contrast reagents, optical reagents, and nuclear reagents. Contrast agents are substances that increase radiodensity and enhance the contrast of tissues or fluids in medical imaging by modifying how electromagnetic radiation or ultrasound waves interact with the body. The technologies involved include nanoparticles, fluorescent dyes, radiopharmaceuticals, fluorescent proteins, and quantum dots, which operate across imaging modalities such as X-ray, CT, ultrasound, and MRI. These reagents are applied in areas including neurological, cardiovascular, cancer, gastrointestinal, musculoskeletal, and nephrological disorders, among others, and are used by end users such as biotechnology firms, pharmaceutical companies, and diagnostic laboratories.

The medical imaging reagents market consists of sales of fluorescent visualizing reagents, supermolecules, and magnetic resonance imaging reagents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.